Cui Junming suggested that the government consider purchasing Johnson & Johnson vaccines, saying that the data is more complete and only one dose is required

Social News

Written by: Zhang Jiamin

2021-03-16 11:23

Last update date: 2021-03-16 11:24

People in many European countries have experienced thromboembolism after being vaccinated with the AstraZeneca vaccine. Hong Kong has also purchased the Oxford-AstraZeneca vaccine.

Cui Junming, president of the Hong Kong Institute of Hospital Pharmacists, pointed out on the Hong Kong and Taiwan program "Millennium" today (16th) that there is little chance that vaccination will cause blood clots.

Regarding the government's proposed procurement of the fourth vaccine, he suggested that the authorities should consider purchasing the vaccine developed by Johnson & Johnson Pharmaceuticals. He also pointed out that the vaccine only needs one dose and has more complete data.

▼Fobitai vaccination on the first day of March 10▼

+14

+14

+14

Cui Junming, president of the Hong Kong Institute of Hospital Pharmacists, pointed out on the Hong Kong and Taiwan program "Millenniums" this morning that vaccination may accelerate vascular occlusion, but he believes that stress and smoking may also cause related situations. He believes that vaccination may not be necessary It's a big deal.

The "adjuvant" in the vaccine may cause abnormalities after vaccination.

He pointed out that generally inactivated vaccines are added with "adjuvants" to stimulate the immune system and make the vaccine more responsive.

Inoculation failure occurs mostly in the second dose

Cui Junming suggested that the government should consider the vaccine developed by Johnson & Johnson when purchasing the fourth vaccine.

Cui pointed out that the advantage of this vaccine is that it only requires one dose. He believes that the current vaccination failure mostly occurs in the second dose, because some people are afraid of side effects, or mistakenly think that the second dose is unnecessary.

He also pointed out that the United States currently has the most complete data on vaccines developed by Johnson & Johnson, among which the number of elderly people is twice that of Fubital.

He pointed out that although the effective rate of Johnson & Johnson's vaccine is 66%, which is lower than that of Fubitai, Johnson & Johnson's data includes moderate to severe patients, while Fubitai includes young patients.

Foreign domestic helpers accept vaccinations, priority group groups complain about lack of information and employers are under pressure to vaccinate

New Crown Vaccine | 01 Actual measurement requires 18 minutes to wait for online injections

The Medical Association approves the general guidelines of the Department of Health and should mention more data to prove that the accident has nothing to do with the new crown vaccine

Nie Dequan: Expansion of vaccination to 30 years old, increase of working population, saying that the epidemic has not subsided, one wave is rising

01News

New crown pneumonia new crown vaccine